Madrigal Pharmaceuticals Welcomes Jackie Fouse to Board of Directors

Madrigal Pharmaceuticals has appointed seasoned biotech executive Jackie Fouse, Ph.D., to its Board of Directors as the company continues its mission to transform treatment for metabolic dysfunction-associated steatohepatitis (MASH). With more than 30 years of experience in healthcare and finance, including leadership roles at Agios Pharmaceuticals and Celgene, Fouse is set to bring valuable expertise to Madrigal as it advances its newly launched MASH treatment, Rezdiffra. Her appointment follows the planned retirement of longtime board member Fred Craves, Ph.D., in July 2025.

Company leaders expressed enthusiasm about Fouse’s addition to the board, recognizing her deep industry knowledge and strategic insights. “Jackie’s leadership will be invaluable as we expand geographically, advance our clinical programs, and build on the success of Rezdiffra,” said Bill Sibold, CEO of Madrigal. Fouse shared her excitement about joining the board, praising Madrigal for breaking through years of challenges in MASH drug development with the first approved treatment. She looks forward to working alongside the team to drive the company’s continued growth and innovation in the field.